Skip to main content

Table 3 Meta analysis results for the association of over-expressed SNHG20 with clinicopathological parameters

From: Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis

Categories Studies (n) Number of patients OR (95% CI) P value Heterogeneity Begg Egger
I2 (%) P value Model
Gender (male vs female) 13 1034 0.96 (0.74, 1.25) 0.763 0.00 0.607 Fixed-effect 0.951 0.792
Smoking status (yes vs no) 3 137 1.16 (0.59, 2.28) 0.676 0.00 0.439 Fixed-effect
Distant metastasis (yes vs no) 5 502 1.28 (0.35, 4.71) 0.706 84.50 0.000 Random-effect
TNM stage (III/IV vs I/II) 9 591 2.80 (2.00, 3.93) 0.000 13.90 0.318 Fixed-effect 0.348 0.389
Tumor size (> 5 cm vs < 5 cm) 6 478 3.08 (2.11, 4.51) 0.000 0.00 0.753 Fixed-effect
Lymph node metastasis (yes vs no) 8 534 2.99 (2.08, 4.31) 0.000 45.00 0.079 Fixed-effect
Tumor stage (T3/T4 vs T1/T2) 3 203 4.51 (2.17, 9.37) 0.000 0.00 0.943 Fixed-effect
Histological grade (poorly vs well/moderately) 9 844 1.95 (1.44, 2.63) 0.000 6.00 0.385 Fixed-effect 0.602 0.575
  1. OR odd ratio, 95% CI confidence interval